BeiGene
BGNE
$290.61
Share price
0.49%
Change (1 day)
35.28%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
Earnings for BeiGene (BGNE)
Earnings in 2024 (TTM): -A$1.3 Billion
According to BeiGene 's latest financial reports the company's current earnings are A$3.31 Billion. In 2023 the company made an earning of -A$1.91 Billion, an increase over its 2022 earnings that were of -A$2.82 Billion. The earnings displayed on this page is the company's Pretax Income.
Earnings history for BeiGene from 2015 to 2024
Annual earnings
| Year | Earnings | Change |
|---|---|---|
2024 (TTM)  | -A$1.3 Billion | -31.67% |
| 2023 | -A$1.91 Billion | -32.52% |
| 2022 | -A$2.82 Billion | 24.39% |
| 2021 | -A$2.27 Billion | -13.21% |
| 2020 | -A$2.61 Billion | 72.69% |
| 2019 | -A$1.52 Billion | 36.01% |
| 2018 | -A$1.12 Billion | 616.83% |
| 2017 | -A$0.16 Billion | -15.24% |
| 2016 | -A$0.19 Billion | 107.91% |
| 2015 | -A$87.91 Million |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 | -A$28.57 Million | -97.92% | 🇺🇸 USA |
 | -A$16.31 Million | -98.81% | 🇺🇸 USA |